Study Reveals High Rates of Treatment Resumption Among GLP-1 Users
A recent study presented at the Endocrine Society’s annual meeting, ENDO 2026, highlights a complex pattern of adherence among patients using GLP-1 receptor agonists for type 2 diabetes. While discontinuation rates are significant—with nearly 60% of patients stopping their medication within two years—the research reveals that these pauses are often temporary. Approximately 58% of those who discontinue treatment eventually resume therapy within two years, suggesting that the clinical journey for these patients is frequently characterized by a 'start-and-stop' cycle rather than permanent cessation.
Analyzing insurance claims for over 60,000 patients, researchers identified several factors influencing treatment persistence. Gastrointestinal side effects, such as nausea, remain a primary driver for discontinuation. Furthermore, socioeconomic factors play a role, with patients covered by Medicare or Medicaid and Black patients showing higher rates of treatment interruption. Conversely, the study found that patients initiated on treatment by endocrinologists were more likely to remain on their medication, suggesting that specialized oversight may improve long-term adherence.
The data also underscores the impact of pharmaceutical innovation on patient behavior. Newer medications, particularly tirzepatide and semaglutide, demonstrated significantly higher persistence rates compared to older alternatives like liraglutide. Patients on newer therapies were notably less likely to stop their treatment, indicating that advancements in drug formulation may be helping patients manage side effects or achieve better outcomes, thereby encouraging continued use.
These findings are critical for the healthcare industry, as consistent adherence to GLP-1 therapy is essential for mitigating the long-term risks associated with type 2 diabetes, including cardiovascular events and kidney disease. By understanding the patterns of discontinuation and reinitiation, providers and policymakers can better identify high-risk groups who require additional support. Targeted interventions, such as improved patient education or closer monitoring during the initial months of treatment, could help stabilize therapy and ensure patients receive the full protective benefits of these medications.